ADHD Medications For Children: New Zealand Guide To Treatments
Explore effective medications for managing ADHD in children, including types, benefits, side effects, and latest prescribing updates in New Zealand.
Attention Deficit Hyperactivity Disorder (ADHD) affects many children, impacting their focus, behavior, and daily functioning. Medications play a key role in treatment, often combined with therapy and support strategies. In New Zealand, options like stimulants and non-stimulants help manage symptoms effectively when prescribed appropriately.
Understanding ADHD and the Role of Medication
ADHD involves challenges with attention, hyperactivity, and impulsivity. For children, this can disrupt school, home life, and social interactions. Medications target brain chemicals like dopamine and norepinephrine to improve concentration and self-control. They are most effective as part of a broader plan including behavioral interventions.
Stimulants are typically first-line treatments due to their quick action and strong evidence base. Long-term studies show safety over decades when monitored properly. Non-stimulants offer alternatives for those who don’t respond well to stimulants or experience intolerable side effects.
Primary Stimulant Options: Methylphenidate
Methylphenidate is the preferred initial medication in New Zealand for its flexible dosing. It boosts dopamine levels by blocking reuptake, enhancing focus and reducing impulsivity. Available since 1970, formulations suit various needs.
- Immediate-release (Ritalin, Rubifen 10mg tablets): Acts in 30-60 minutes, lasts 3-4 hours. Useful for short school periods but may cause ‘rebound’ effects like fatigue when wearing off.
- Sustained-release (Rubifen SR 20mg): Smoother action over 6 hours, taken 2-3 times daily. Better for avoiding peaks and troughs.
- Extended-release (Ritalin LA, Concerta): Lasts 8-12 hours. Ritalin LA releases half immediately and half later; not to be crushed. Ideal for full-day coverage.
Dosing starts low, titrated based on response. Target is symptom control with minimal side effects. Special Authority approval is required for funding, but approvals are now indefinite since December 2024.
Alternative Stimulants: Amphetamine-Based Treatments
Amphetamines like lisdexamfetamine and dexamfetamine provide options when methylphenidate isn’t suitable. They increase dopamine and norepinephrine release.
| Medication | Form | Duration | Notes |
|---|---|---|---|
| Lisdexamfetamine (Vyvanse) | Capsules 10-100mg | 10-14 hours | Prodrug converts slowly; smooth effect, less abuse potential. For ages 6+. |
| Dexamfetamine | Tablets | 4-6 hours | Unapproved for ADHD but used off-label; shorter acting. |
Lisdexamfetamine suits children needing long coverage. Dosing builds gradually over 4-6 weeks to assess benefits.
Non-Stimulant Choices: Atomoxetine and Beyond
Atomoxetine (Strattera) is a non-stimulant norepinephrine reuptake inhibitor. It takes weeks to work fully but avoids stimulant side effects. Target dose: 1.2-1.4 mg/kg daily, max 100mg. Good for anxiety comorbidity.
Other non-stimulants like modafinil (not funded) may help mildly but are less potent. Antidepressants (SSRIs, SNRIs) are second-line, used cautiously with monitoring.
Recent Updates in Prescribing Access
From February 1, 2026, GPs and nurse practitioners can initiate psychostimulants for adults without specialist referral. For children, specialists still lead, but changes ease overall access. No more two-year renewals for Special Authorities; funding expanded for lisdexamfetamine.
These shifts address wait times and treatment gaps, as adult dispensing rises while pediatric rates lag prevalence.
Managing Side Effects and Monitoring
Common side effects include appetite loss, sleep issues, headaches, and growth slowing (usually temporary). Monitor height, weight, blood pressure, and heart rate regularly. Strategies like drug holidays can mitigate growth concerns.
- Appetite suppression: Offer calorie-dense foods, dose after meals.
- Sleep problems: Time doses early, consider formulations.
- Mood changes: Rare, but watch for tics or anxiety.
- Cardiac risks: Screen for heart conditions pre-treatment.
Annual reviews ensure ongoing suitability. Abrupt stops can worsen symptoms; taper if discontinuing.
Combining Medication with Lifestyle Support
Medications work best alongside therapy. Behavioral programs teach coping skills. School accommodations, exercise, and routines enhance outcomes. Parental education is vital for adherence.
Special Considerations for Different Age Groups
For ages 6+, stimulants are standard. Under 6, non-pharmacological first; meds if severe. Adolescents may need dose adjustments for growth spurts.
Frequently Asked Questions (FAQs)
Are ADHD medications addictive for children?
When used as prescribed, risk is low. Long-acting forms reduce abuse potential. Monitoring prevents misuse.
How quickly do they work?
Stimulants: 30-60 minutes. Non-stimulants: 1-4 weeks.
Do they cure ADHD?
No, they manage symptoms. Lifelong strategies often needed.
What if my child doesn’t respond to methylphenidate?
Switch to amphetamines or non-stimulants. Specialist reassessment helps.
Are generics as effective?
Yes, but some prefer brands for consistency. Funded options available.
Accessing Treatment in New Zealand
Start with GP referral to pediatrician/psychiatrist. Special Authority covers costs. Stock issues may require brand switches, but approvals adapt.
References
- ADHD Medication | Auckland Neuropsychiatry — Neuropsychiatry.co.nz. Accessed 2026. https://www.neuropsychiatry.co.nz/medication-for-adhd
- Changes to psychostimulant medicines prescribing for ADHD — bpac.org.nz. 2026-02-01. https://bpac.org.nz/2026/adhd-brief.aspx
- Spotlight on lisdexamfetamine — Medsafe.govt.nz. 2024-03. https://www.medsafe.govt.nz/profs/PUArticles/March2024/Spotlight-on-lisdexamfetamine.html
- Dispensing of attention-deficit hyperactivity disorder medications — PubMed.ncbi.nlm.nih.gov. 2024. https://pubmed.ncbi.nlm.nih.gov/38696829/
- Methylphenidate For ADHD — Kidshealth.org.nz. Accessed 2026. https://www.kidshealth.org.nz/methylphenidate-for-adhd
- Changes for prescribing ADHD medications — Beehive.govt.nz. Accessed 2026. https://www.beehive.govt.nz/release/changes-prescribing-adhd-medications
- Decision to change the regulatory and funding restrictions — Pharmac.govt.nz. 2025-06. https://www.pharmac.govt.nz/news-and-resources/consultations-and-decisions/2025-06-decision-to-change-the-regulatory-and-funding-restrictions-for-stimulant-medicines-for-adhd
Similar Articles
Read full bio of Sneha Tete
